Literature DB >> 21805244

Identification of the myosin heavy polypeptide 9 as a downstream effector of the proprotein convertases in the human colon carcinoma HT-29 cells.

Nathalie Scamuffa1, Peter Metrakos, Fabien Calvo, Abdel-Majid Khatib.   

Abstract

In addition to the large spectrum of the protein precursors processed and activated by the proprotein convertases (PCs) that are crucial for the maintenance of the malignant phenotype of colon cancer cells such as matrix metalloproteases, adhesion molecules, growth factors, and growth factor receptors, the PCs also regulate the expression and the activity of other proteins that are not PC substrates and involved in the acquisition of the metastatic and tumorigenic potential of these tumor cells. The identification in colon cancer cells of such proteins is thereby crucial for the understanding of the cascade of molecular events regulated by the PCs leading to tumorigenesis and metastasis and thus may constitute potential candidates for new colon cancer-specific targets and/or biomarkers. Using the human colon cancer cells HT-29 and ProteinChip arrays analysis that apply the surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), we identified the myosin heavy polypeptide 9 as new downstream effector of PCs in these cells. This protein was reported to be involved in the processes of malignant epithelial transformation and its role in colon cancer is unknown.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805244     DOI: 10.1007/978-1-61779-204-5_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activation.

Authors:  Fabienne Soulet; Clement Bodineau; Katarzyna B Hooks; Jean Descarpentrie; Isabel Alves; Marielle Dubreuil; Amandine Mouchard; Malaurie Eugenie; Jean-Luc Hoepffner; Jose J López; Juan A Rosado; Isabelle Soubeyran; Mercedes Tomé; Raúl V Durán; Macha Nikolski; Bruno O Villoutreix; Serge Evrard; Geraldine Siegfried; Abdel-Majid Khatib
Journal:  JCI Insight       Date:  2020-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.